NCCN updates NHL guidelines to reflect recent FDA drug approvals

The National Comprehensive Cancer Network, an alliance of twenty-one of the nation's top cancer centers and hospitals under the auspices of the National Cancer Institute, is updating its published treatment guidelines for non-Hodgkin's lymphomas to reflect the US FDA's three recent drug treatment approvals:

- In September 2009 Folotyn (pralatrexate) became the first treatment ever approved by the FDA for peripheral T-cell lymphoma (PTCL).
- In October 2009 the agency approved the monoclonal Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL) whose disease had failed to respond to chemotherapy.
- In November 2009 the agency approved Istodax injection (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL), becoming the fourth such drug approved for CTCL, along with Zolinza (vorinostat), Ontak (denileukin difitox), and Targretin (bexarotene).

Although the updates are already in place, all changes to the NCCN's Clinical Practice Guidelines in Oncology first undergo a rigorous scientific, evidence-based process of review by physicians from NCCN member hospitals and institutions.

By Ross Bonander

Source: PR Newswire

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap